Inactivating <i>NF1</i> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance
Alex Pearson(Breast Cancer Now), Nicholas C. Turner(Royal Marsden NHS Foundation Trust)
Cited by 136
Related Papers
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
|Annals of Oncology|2022|633
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
|Clinical Cancer Research|2010|323
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
|Nature Communications|2020|258